Abstract 100P
Background
To explore the clinical feasibility of the patient-derived tumor xenograft (PDTX or PDX) mouse model in guiding the individualized precise treatment of advanced digestive system tumors through a multicenter clinical study.
Methods
14 centers participated the trial in China. Fresh tumor tissues were obtained by surgery and biopsy, then engrafted subcutaneously into immune deficient mice. When the tumor volume grew to 60 mm3, the modeling was successful. The consistency of the original tissue (PA) and the engrafted tissue (P0) was analyzed by pathological comparison. The tumorigenesis time model was recorded. After successful modeling, medication was administered in groups according to the recommended regimen for 21 days. The tumor growth inhibition rate (TGI) was recorded and evaluated as positive if TGI > 60%. According to RECIST 1.1, DCR (SD, PR, CR) was evaluated as positive in clinical synchronous treatment. The two results were compared to evaluate the accuracy of guiding clinical medication.
Results
A total of 33 patients with different advanced digestive system tumors were included, including 2 cases of esophageal cancer, 10 cases of colorectal cancer, 10 cases of pancreatic cancer, 5 cases of gastric cancer, 3 cases of liver cancer, 2 cases of duodenal adenocarcinoma and 1 case of gallbladder cancer. The successful rate of tumor xenograft modeling was 75.8% (25/33), including 78.3% (18/23) in small samples and 70% (7/10) in surgical samples. Pathological results showed that the consistency of P0 and PA was 100% in 25 cases. The average tumorigenesis time of PDTX model was 42 days. Pharmacodynamic tests were completed in 17 cases, including 28 kinds of drugs and 49 regimens. The clinical efficacy of 10 regimens in 9 patients were evaluated as PR in 2 cases, SD in 6 cases and PD in 2 cases. The results of pharmacodynamic test were consistent with clinical synchronous efficacy.
Conclusions
PDTX mouse model has high successful modeling rate with the biological and pathological characteristics of primary tumor, and the results of pharmacodynamic test are highly consistent with the clinical efficacy. It can be used as a individualized diagnosis and treatment technique of advanced gastrointestinal tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Nanjing Personal Oncology Biotechnology Co. Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session